# Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

> **NCT03872596** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 58 (actual)

## Conditions studied

- Bipolar Disorder
- Schizophrenia

## Interventions

- **DRUG:** Seroquel IR 300mg
- **DRUG:** Seroquel IR 25mg
- **DRUG:** Quetiapine Formulation A 300mg
- **DRUG:** Quetiapine Formulation B 300mg
- **DRUG:** Quetiapine Formulation 25mg

## Key facts

- **NCT ID:** NCT03872596
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-27
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-11-27
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03872596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03872596, "Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03872596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*